Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ruth Salmon"'
Autor:
Georg Schett, Fan Wu, Nikolay Delev, Ruth Salmon, Jerill Thorpe, Amitkumar Mehta, Tatyana Feldman, Jeremy Abramson, Boyu Hu, Fabien Müller, Ashley Koegel, Divya Varun, Alison Maier, David Kugler, Matthew Westoby
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/ac8828bfb2494c95a4e57d7e20c595b5
Autor:
Andreia Costa, Gail Turner, Gabriela Diaz, Yeonjoo Oh, Jianguo Huang, Jenna Bailey, Cyr De Imus, Stephanie Busch, Teresa Foy, Pallavur Sivakumar, Ruth Salmon, Cédric Cleyrat
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/4fe430d5561d401db02794a184cc61a6
Publikováno v:
Bulletin of the World Health Organization, Vol 88, Iss 3, Pp 235-236 (2010)
Externí odkaz:
https://doaj.org/article/58d63979173e4ed6864cf166a1cc1387
Autor:
Michael Ports, Jon C. Jones, Timothy G. Johnstone, Jim Qin, Seamus P. Ragan, Ruth Salmon, Ronald J. Hause, Alex Baturevych, Cecile M. Krejsa, Christopher R. Clouser, Rafael Angel Ponce
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19+ B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor envir
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for patients with CD19+ B-cell malignancies. Combination strategies that improve CAR T-cell potency, limit tumor envir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47988262cbbdd3e4f3972b57fc6a833b
http://europepmc.org/articles/PMC7144752
http://europepmc.org/articles/PMC7144752
Autor:
Alex Baturevych, Yue Jiang, Michael Ports, Patrick Carlson, Heidi K. Jessup, David G. Kugler, Neha Soni, Ronald J. Hause, Catherine Sierra, Christopher R. Clouser, Collin Hauskins, Jon C. Jones, Timothy G. Johnstone, Lindsey Wimberly, Melissa Works, Ruth Salmon, Wendy Curtis, Blythe D. Sather
Publikováno v:
Molecular cancer therapeutics. 18(12)
Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells have shown promising clinical responses in patients with relapsed/refractory multiple myeloma. Lenalidomide, an immunomodulatory drug, potentiates T cell functionality, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9caecea46418a9d2776b32c8698555d3
https://pubmed.ncbi.nlm.nih.gov/31395689
https://pubmed.ncbi.nlm.nih.gov/31395689
Autor:
Heidi K. Jessup, Ruth Salmon, Jim Qin, Evan Paul Thomas, Melissa Works, Oleksandr Baturevych, Aye T. Chen, Michael Ports, Yue Jiang, Neha Soni
Publikováno v:
Cancer Research. 79:2320-2320
Lisocabtagene maraleucel (liso-cel) is an investigational drug product composed of autologous CD8+ and CD4+ T cells expressing a CD19-specific chimeric antigen receptor (CAR), being evaluated in clinical trials for treatment of B cell malignancies. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::200dd74556fdfe07d37445d5e56e5eab
https://doi.org/10.1158/1538-7445.am2019-2320
https://doi.org/10.1158/1538-7445.am2019-2320
Autor:
Ruth Salmon, Eric M. Chadwick, Bailey Donahue, Melissa Chin, G. Grant Welstead, Clay Patton, Blythe D. Sather, Stephen Michael Burleigh, Dean Y. Toy, Brian J. Belmont, David Jeffrey Huss, Alexandra Croft, Stephen J. Goldfless, Cameron S. Brandt
Publikováno v:
Cancer Immunology Research. 7:A027-A027
Background: Adoptive T-cell therapy with engineered T-cell receptors (eTCR) has demonstrated promising, yet modest clinical benefit to date. Key obstacles for this technology are 1) competition with the endogenous TCR for CD3 components that are requ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3c119b6b86fcccb5af7ff0ffe56dc0b
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-a027
https://doi.org/10.1158/2326-6074.cricimteatiaacr18-a027
Autor:
William Eckersley, Ruth Salmon
Publikováno v:
Development in Practice. 20:726-733
Traffic crashes kill 1.2 million people annually, and the number is growing fast, particularly in developing countries. Although child road-safety education is widely considered important, few programmes have resulted in demonstrated improvements in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04664d5093f2a02ab231cb80d2e3c63b
https://doi.org/10.1080/09614524.2010.491531
https://doi.org/10.1080/09614524.2010.491531
Publikováno v:
Blood. 128:3231-3231
Chronic lymphocytic leukemia (CLL) drives systemic immune suppression and T cell dysfunction in patients, highlighting an important consideration in this setting for the manufacturing and efficacy of adoptive cell therapies using autologous T cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd61aed1303c7300a8c427f7a0f1a99
https://doi.org/10.1182/blood.v128.22.3231.3231
https://doi.org/10.1182/blood.v128.22.3231.3231
Autor:
Will Selleck, Blythe D. Sather, Jon C. Jones, G. Grant Welstead, Christopher Heath Nye, Alex Baturevych, Justin Fang, McKensie Collins, Hari Jayaram, Frank Buquicchio, Sherri Mudri, David Bumcrot, Ruth Salmon
Publikováno v:
Molecular Therapy. 24:S229
Cancer immunotherapy is an exciting area of cancer treatment bolstered by recent success of anti-immune checkpoint antibodies in the clinic. Engineered T cells that are programmed to attack tumors via chimeric antigen receptors (CARs) have also shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31a8e95f7462c6aee43b4c2510b439e8
https://doi.org/10.1016/s1525-0016(16)33380-9
https://doi.org/10.1016/s1525-0016(16)33380-9